The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update.
Aleksandar Sekulic
Consultant or Advisory Role - Roche/Genentech
Michael R Migden
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Anthony E Oro
Research Funding - Roche
Karl D Lewis
Consultant or Advisory Role - Genentech
Research Funding - Genentech
John D Hainsworth
No relevant relationships to disclose
Simon Yoo
No relevant relationships to disclose
Luc Dirix
No relevant relationships to disclose
Jeannie Hou
Employment or Leadership Position - Genentech
Huibin Yue
Employment or Leadership Position - Genentech
Axel Hauschild
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche